Cannabis R&D Firms See Wild Growth Curve

The country’s health administration is scrambling to deal with the onslaught and the rush is having unexpected side effects. Namely, Health Canada is increasing licenses for Access to Cannabis for Medical Purposes Regulations (ACMPR) licences. This shift is positioning several Canadian RD and testing companies at the forefront of the greatest growth industry in the country.

Markets are keen on the trend and it’s reflecting in these company’s share values.

Atop the list is Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF), which is set to make some major inroads with its licensed testing and timely extraction capabilities – one of very few public companies with this profile.

Also noteworthy is CanniMed Therapeutics Inc. (TSX: CMED) (CMMDF) that reached a high of $13.35 in early 2017 and has currently pulled back to the

... read more at: http://www.prnewswire.co.uk/news-releases/cannabis-rd-firms-see-wild-growth-curve-643940773.html

by

Leave a Reply

Your email address will not be published. Required fields are marked *